The global crisis caused by the coronavirus has disrupted our personal and professional lives in ways that seemed inconceivable only a few
months ago. This is also true for the conduct and operation of ongoing clinical trials. Denis Curtin and Bill Byrom at Signant Health look at
how social distancing rules, and reluctance to visit public places have presented significant challenges for the continued operation of studies
and the collection of important clinical endpoint data.